On Mar. 24, 2020, Novavax announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant, in adults aged 65 and older.

Using the FDA criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzoneﾮ Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.